Author:
van Draanen Jenna,Hamilton Jonah,Morgan Jeffrey,Maxwell Scott,Taylor Tara,Richardson Lindsey,Nolan Seonaid
Abstract
Abstract
Background
The potential public health benefits of supervised smoking facilities (SSFs) are considerable, and yet implementation of SSFs in North America has been slow. We conducted this study to respond to significant knowledge gaps surrounding SSF utilization and to characterize substance use, harm reduction practices, and service utilization following the onset of the COVID-19 pandemic.
Methods
A questionnaire was self-administered at a single site by 175 clients using an outdoor SSF in Vancouver, Canada, between October–December 2020. Questionnaire responses were summarized using descriptive statistics. Multinomial logistic regression techniques were used to examine factors associated with increased SSF utilization.
Results
Almost all respondents reported daily substance use (93% daily use of opioids; 74% stimulants). Most used opioids (85%) and/or methamphetamine (66%) on the day of their visit to the SSF. Respondents reported drug use practice changes at the onset of COVID-19 to reduce harm, including using supervised consumption sites, not sharing equipment, accessing medically prescribed alternatives, cleaning supplies and surfaces, and stocking up on harm reduction supplies. Importantly, 45% of SSF clients reported using the SSF more often since the start of COVID-19 with 65.2% reporting daily use of the site. Increased substance use was associated with increased use of the SSF, after controlling for covariates.
Conclusions
Clients of the SSF reported increasing not only their substance use, but also their SSF utilization and harm reduction practices following the onset of COVID-19. Increased scope and scale of SSF services to meet these needs are necessary.
Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Public Health, Environmental and Occupational Health,Medicine (miscellaneous)
Reference36 articles.
1. Hedrich D, Kerr T, Dubois-Arber F. Drug consumption facilities in Europe and beyond. Harm reduction: Evidence, impacts, and challenges. 2010;305–32.
2. Kennedy MC, Karamouzian M, Kerr T. Public health and public order outcomes associated with supervised drug consumption facilities: a systematic review. Curr HIV/AIDS Rep. 2017;14(5):161–83.
3. Marshall BDL, Milloy MJ, Wood E, Montaner JSG, Kerr T. Reduction in overdose mortality after the opening of North America’s first medically supervised safer injecting facility: a retrospective population-based study. The Lancet. 2011;377(9775):1429–37.
4. Levengood TW, Yoon GH, Davoust MJ, Ogden SN, Marshall BDL, Cahill SR, et al. Supervised injection facilities as harm reduction: a systematic review. Am J Prev Med. 2021;61(5):738–49.
5. United Nations. World Drug Report. 2019. Obtained October 18, 2022 from https://wdr.unodc.org/wdr2019/
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献